Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Advertising, Marketing & Sales Business Strategies Commercial

Novartis On Its ‘US First’ Commercial Plan

  • Interviews

Executive Summary

US Innovative Medicines president Victor Bulto talked to Scrip about why the company is pivoting to a commercial strategy that prioritizes the US and what that means for developing and selling drugs.

You may also be interested in...



Novartis Culls Pipeline As ‘Pure-Play’ Drive Progresses

The Swiss company has raised its 2023 forecast thanks to stronger Q1 sales, but its transformation towards a more ‘pure-play’ pharma company is still a work in progress.

European Pharma 2023: A Rocky Year For Roche But Novo Is Rising Fast

Roche remains the European sector’s biggest company despite a wobble in 2022, but Novo Nordisk’s spectacular growth has seen it overtake AstraZeneca and Novartis in market cap terms.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: the best of J.P. Morgan; Novartis on its US-first commercial plan; Chugai CEO talks to Scrip on the Roche alliance and more; Scrip Asks what this year holds for pricing and reimbursement; and the global outlook for biopharma funding.

Table

View full table

Related Content

Scrip
Scrip
Scrip
Scrip

Topics

Related Companies

Tags:
Advertising, Marketing & Sales Business Strategies Commercial
Latest Headlines

BIO Notebook: GSK’s Walmsley On M&A; Merck On How Falling Valuations Are Affecting Deals

ASCO 2023 – Novartis’s Adjuvant Breast Cancer Win Comes With Caveats

ASCO 2023 – Roche Sees Morpheus And Takes The Red Pill

ASCO 2023 – Bicara Eyes Head And Neck Niche

See All
UsernamePublicRestriction

Register

SC147679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By